MX2020002560A - Tratamiento con mazindol de la dependencia a la heroina y el trastorno de uso de sustancias. - Google Patents
Tratamiento con mazindol de la dependencia a la heroina y el trastorno de uso de sustancias.Info
- Publication number
- MX2020002560A MX2020002560A MX2020002560A MX2020002560A MX2020002560A MX 2020002560 A MX2020002560 A MX 2020002560A MX 2020002560 A MX2020002560 A MX 2020002560A MX 2020002560 A MX2020002560 A MX 2020002560A MX 2020002560 A MX2020002560 A MX 2020002560A
- Authority
- MX
- Mexico
- Prior art keywords
- mazindol
- substance
- treatment
- substance use
- use disorder
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762555469P | 2017-09-07 | 2017-09-07 | |
| PCT/IB2018/001138 WO2019058172A1 (en) | 2017-09-07 | 2018-09-06 | MAZINDOLE TREATMENT FOR HEROID DEPENDENCE AND DISORDER RELATED TO THE USE OF PSYCHOACTIVE SUBSTANCES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020002560A true MX2020002560A (es) | 2020-07-13 |
Family
ID=64316589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020002560A MX2020002560A (es) | 2017-09-07 | 2018-09-06 | Tratamiento con mazindol de la dependencia a la heroina y el trastorno de uso de sustancias. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11596622B2 (https=) |
| EP (1) | EP3678661A1 (https=) |
| JP (1) | JP7593619B2 (https=) |
| KR (1) | KR20200085730A (https=) |
| CN (1) | CN111343979A (https=) |
| BR (1) | BR112020004506A2 (https=) |
| CA (1) | CA3074054A1 (https=) |
| MX (1) | MX2020002560A (https=) |
| WO (1) | WO2019058172A1 (https=) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5217987A (en) | 1989-10-30 | 1993-06-08 | Berger Stephen P | Dopamine uptake inhibitors in reducing substance abuse and/or craving |
| US6323242B1 (en) | 1998-12-02 | 2001-11-27 | Peter Sterling Mueller | Treatment of disorders secondary to organic impairments |
| US9655865B2 (en) | 2002-07-29 | 2017-05-23 | Veroscience, Llc | Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes |
| FR2899476B1 (fr) | 2006-04-11 | 2008-07-04 | Assist Publ Hopitaux De Paris | Association du mazindol dans le traitement du deficit de l'attention/hyperactivite |
| WO2009029308A1 (en) | 2007-08-27 | 2009-03-05 | University Of Virginia Patent Foundation | Medication combinations for the treatment of alcoholism and drug addiction |
| JP2013523757A (ja) | 2010-03-31 | 2013-06-17 | スパーナス ファーマシューティカルズ インコーポレイテッド | マジンドールの製剤 |
| US9687445B2 (en) * | 2012-04-12 | 2017-06-27 | Lts Lohmann Therapie-Systeme Ag | Oral film containing opiate enteric-release beads |
| JP6584745B2 (ja) | 2014-04-09 | 2019-10-02 | 和久 前田 | 抗肥満薬の効果を向上させる組成物の製造方法。 |
| ES2884973T3 (es) | 2016-03-09 | 2021-12-13 | Nls Pharmaceutics Ag | Comprimido multicapa de mazindol de IR/SR y su utilización para el tratamiento del trastorno por déficit de atención/hiperactividad (ADHD) |
-
2018
- 2018-09-06 MX MX2020002560A patent/MX2020002560A/es unknown
- 2018-09-06 BR BR112020004506-3A patent/BR112020004506A2/pt not_active Application Discontinuation
- 2018-09-06 KR KR1020207009439A patent/KR20200085730A/ko not_active Ceased
- 2018-09-06 WO PCT/IB2018/001138 patent/WO2019058172A1/en not_active Ceased
- 2018-09-06 CN CN201880070488.1A patent/CN111343979A/zh active Pending
- 2018-09-06 US US16/645,306 patent/US11596622B2/en active Active
- 2018-09-06 JP JP2020513594A patent/JP7593619B2/ja active Active
- 2018-09-06 CA CA3074054A patent/CA3074054A1/en active Pending
- 2018-09-06 EP EP18803756.8A patent/EP3678661A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3074054A1 (en) | 2019-03-28 |
| US11596622B2 (en) | 2023-03-07 |
| EP3678661A1 (en) | 2020-07-15 |
| US20210161865A1 (en) | 2021-06-03 |
| JP2020533295A (ja) | 2020-11-19 |
| WO2019058172A1 (en) | 2019-03-28 |
| BR112020004506A2 (pt) | 2020-09-15 |
| JP7593619B2 (ja) | 2024-12-03 |
| CN111343979A (zh) | 2020-06-26 |
| KR20200085730A (ko) | 2020-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018500642A1 (en) | Anti-garp antibody | |
| MX2014010590A (es) | Terapia de combinacion para trastornos proliferativos. | |
| SG10201811128RA (en) | Ezh2 inhibitors for treating lymphoma | |
| MX2020004075A (es) | Composiciones y metodos que comprenden bupropion o compuestos relacionados y dextrometorfano. | |
| WO2015054619A3 (en) | Use of a pcsk9 inhibitor to treat hyperlipidemia | |
| JO3784B1 (ar) | الاستخدام المشترك للاجسمام المضادة pd-1 ومضادات m-csf في علاج السرطان | |
| MX2017017138A (es) | Conjugados homogeneos especificos de sitio con inhibidores de ksp. | |
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| MX2017006437A (es) | Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor. | |
| PH12020550462A1 (en) | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same | |
| CA3010788A1 (en) | Methods of administering vasopressors | |
| HK1218251A1 (zh) | 用拉喹莫德治疗多发性硬化症 | |
| HK1253098A1 (zh) | 用於治疗癌症的mdm2抑制剂的给药方案 | |
| AU2018282105A1 (en) | Dosing of vibegron for treatment of overactive bladder | |
| MX2015013155A (es) | Formulaciones farmaceuticas de la familia de la tetrandrina y metodo. | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| NZ707636A (en) | Ingenol-derived compounds that can be used for treating cancer | |
| CA3011003A1 (en) | Bacterial ghosts for the treatment of cancer | |
| MY197664A (en) | Immunity enhancing agent for cancer by allergin-1 antagonist | |
| PH12018500814A1 (en) | Oxadiazaspiro compounds for the treatment of drug abuse and addiction | |
| PH12018502111A1 (en) | Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis | |
| MY186840A (en) | Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy | |
| ZA202002107B (en) | Use of specific sirna against protein s for the treatment of hemophilia | |
| PH12018550008A1 (en) | Selected amide of y-hydroxybutyric acid and uses thereof in the treatment of alcohol misuse | |
| MX2016006894A (es) | Terapia de combinacion que comprende un inhibidor de jak, cdk y pim. |